(3-(((4-butyl-benzyl)-(1-methyl-1 H-imidazole-4-sulfonyl)-amino)-methyl)-phenyl)-acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3-(((4-butyl-benzyl)-(1-methyl-1 H-imidazole-4-sulfonyl)-amino)-methyl)-phenyl)-acetic acid
• 英文别名: 2-[3-[[(4-Butylphenyl)methyl-(1-methylimidazol-4-yl)sulfonylamino]methyl]phenyl]acetic acid
• 化学式: C₂₄H₂₉N₃O₄S
• 分子量: 455.578
• InChiKey: AAOBOTLNOBXQHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-甲酰基苯乙酸甲酯 在 盐酸 、 NaCNBH3 作用下， 以 1,4-二氧六环 、 甲醇 、 7-(4-thiazol-2-yl-benzylamino)-heptanoic acid methyl ester 为溶剂， 生成 (3-(((4-butyl-benzyl)-(1-methyl-1 H-imidazole-4-sulfonyl)-amino)-methyl)-phenyl)-acetic acid
  参考文献：
  名称：

  Prostaglandin agonists and their use to treat bone disorders

  摘要：

  本发明涉及前列腺素受体激动剂、使用此类前列腺素受体激动剂的方法、含有此类前列腺素受体激动剂的药物组合物以及含有此类前列腺素受体激动剂的试剂盒。这些前列腺素受体激动剂可用于治疗包括骨质疏松症在内的骨骼疾病。

  公开号：

  US06498172B1

文献信息

• Methods of treatment using an EP2 selective receptor agonist
  申请人：Constan A. Alexander

  公开号：US20050203086A1

  公开（公告）日：2005-09-15

  The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP 2 selective receptor agonist.

  本发明涉及使用EP2选择性受体激动剂治疗肺动脉高压、促进关节融合、促进肌腱和韧带修复、减少继发性骨折的发生、治疗缺血性坏死、促进软骨修复、促进肢体移植后的骨愈合、促进肝脏再生、促进伤口愈合、减少胃溃疡的发生、治疗高血压、促进牙齿珐琅质或手指甲和脚趾甲的生长、治疗青光眼、治疗眼高压以及修复由转移性骨疾病引起的损伤的方法。
• Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist
  申请人：Lee G. Andrew

  公开号：US20050065133A1

  公开（公告）日：2005-03-24

  The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP 2 or EP 4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 and an EP 2 or EP 4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.

  本发明涉及制药组合物和治疗方法，包括向需要的患者施用2-烷基亚甲基-19-去氢维生素D衍生物和EP2或EP4选择性激动剂或其药用可接受的盐或前药的组合物。特别地，本发明涉及制药组合物和方法，包括向需要的患者施用2-亚甲基-19-去氢-20(S)-1α,25-二羟基维生素D3和EP2或EP4选择性激动剂或其药用可接受的盐或前药。
• [EN] PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS<br/>[FR] PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES EN TANT QU'INHIBITEURS DE LA PDE 2
  申请人：PFIZER PROD INC

  公开号：WO2005061497A1

  公开（公告）日：2005-07-07

  The invention provides compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds or prodrugs, wherein n, X, and Y are as defined herein; pharmaceutical compositions thereof; combinations thereof; and uses thereof.

  该发明提供了公式（I）的化合物及其前药，以及化合物或前药的药用可接受盐，其中n、X和Y如本文所定义；药物组合物；它们的组合；以及它们的用途。
• Pharmaceutical compositions and methods for administering EP2 receptor selective agonists
  申请人：——

  公开号：US20030166631A1

  公开（公告）日：2003-09-04

  This invention is directed to pharmaceutical compositions and methods comprising prostglandin agonists, specifically EP 2 receptor selective agonists, which are useful to enhance bone repair and healing and restore or augment bone mass in vertebrates, particularly mammals. The EP 2 receptor selective agonists of the present invention are effective in the treatment of conditions such as those in which the patient has delayed or non-union fracture, bone defect, spinal fusion, bone in-growth, cranial facial reconstruction or bone sites at risk for fracture.

  本发明涉及制药组合物和方法，包括前列腺素激动剂，特别是EP2受体选择性激动剂，这些激动剂对于增强脊椎动物（特别是哺乳动物）的骨修复和愈合以及恢复或增加骨量是有用的。本发明的EP2受体选择性激动剂对于治疗患有延迟或非联合骨折、骨缺陷、脊柱融合、骨内生长、颅面重建或易于骨折的骨部位的病情是有效的。
• Treatment of osteoporsis with EP2/EP4 receptor selective agonists
  申请人：——

  公开号：US20010056060A1

  公开（公告）日：2001-12-27

  This invention is directed to methods and pharmaceutical compositions comprising prostaglandin agonists which are userful to prevent bone loss, restore or augment bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass, such as osteoporosis, and/or bone defects in vertebrates, and particularly mammals, including humans. This invention specifically relates to methods and pharmaceutical compositions comprising combinations of EP 2 receptor selective agonists and EP 4 receptor selective agonists and to methods and pharmaceutical compositions comprising agents which are agonists for both the EP 2 receptor and the EP 4 receptor.

  本发明涉及使用前列腺素激动剂的方法和制药组合物，其有助于预防骨质流失，恢复或增加骨量，并增强骨愈合，包括治疗低骨量症状，如骨质疏松症和/或脊椎动物中的骨缺陷，特别是哺乳动物，包括人类。本发明具体涉及包含EP2受体选择性激动剂和EP4受体选择性激动剂的方法和制药组合物，以及包含同时是EP2受体和EP4受体激动剂的药物。